FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Gano Kyle</u>							2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX								olicable) ctor	10% (	Owner
(Last) (First) (Middle) 12780 EL CAMINO REAL						3. Date of Earliest Transaction (Month/Day/Year) 10/16/2015								belov			
(Street) SAN DIEGO CA 92130 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	<b>'</b>			
	Tabl	e I - No	on-Deriv	/ative	Sec	uritie	s Ac	quired	, Dis	posed o	f, or E	Benef	icially	Owne	ed		
1. Title of Security (Instr. 3) 2. Transacti						Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired (A) of (D) (Instr. 3, 4)			and 5) Secu Bene Owne		ities icially d Following	Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership	
				Code	v	Amount	(A) (D)	FI		Trans	action(s)		(Instr. 4)				
Stock	/2015	015		S <sup>(1)</sup>	V	25,000	D	\$4	17.77 <sup>(2)</sup>	5	51,613	D					
	Та													wned			
rative rity or Exercise Price of Derivative Security    Conversion or Exercise (Month/Day/Year)   Execution Date, if any (Month/Day/Year)   Execution Date,			Code (8)	Instr.	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration			Amoun or Numbe of		vative urity	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	(Find the second of the second	(First) ( L CAMINO REAL  EGO CA S  (State) (  Tabl  Security (Instr. 3)  Stock  2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) L CAMINO REAL  EGO CA 92130  (State) (Zip)  Table I - Note    Security (Instr. 3)  Stock  Table II -  Conversion or Exercise   Price of   Derivative    (Month/Day/Year)   3. Transaction   Date   (Month/Day/Year)   3. Deet   Execution   (Month/Day/Year)   1. Deet   Execution   Execution	(First) (Middle)  L CAMINO REAL  EGO CA 92130  (State) (Zip)  Table I - Non-Deriv  Security (Instr. 3)  2. Transa Date (Month/D  Month/D  Stock  10/16  Table II - Derivat (e.g., p  Conversion or Exercise Price of Derivative  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  2. (Month/Day/Year)	(First) (Middle)  (CAMINO REAL  EGO CA 92130  (State) (Zip)  Table I - Non-Derivative (Month/Day/Year)  Stock  Table II - Derivative S (e.g., puts, compore Exercise Price of Derivative (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)	(First) (Middle)  L CAMINO REAL  Table I - Non-Derivative Sec  Security (Instr. 3)  Table II - Derivative Security (Instr. 3)  Table II - Derivative Security (e.g., puts, calls, If Amen (Month/Day/Year)  2. Table II - Derivative Security (e.g., puts, calls, If Amen (Month/Day/Year))  3. Transaction Date (Month/Day/Year)  2. Table II - Derivative Security (e.g., puts, calls, If Amen (Month/Day/Year))  3. Transaction Date (Month/Day/Year)  3. Transaction Code (Instr. 8)	(First) (Middle)  L CAMINO REAL  (State) (Zip)  Table I - Non-Derivative Securities (Month/Day/Year)  Stock  Table II - Derivative Securities (e.g., puts, calls, warr  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  Stock  Table II - Derivative Securities (e.g., puts, calls, warr  (Month/Day/Year)  A. Transaction Date (e.g., puts, calls, warr  (Month/Day/Year)  A. Transaction Code (Instr. 8)  Security (A) o Dispo of (D) (Instr. and 5	(First) (Middle)  L CAMINO REAL  (State) (Zip)  Table I - Non-Derivative Securities Accurity (Instr. 3)  (Stock 10/16/2015  Table II - Derivative Securities Acquee.g., puts, calls, warrants, (Month/Day/Year)  Table II - Derivative Securities Acquee.g., puts, calls, warrants, (Month/Day/Year)  Table II - Derivative Securities Acquee.g., puts, calls, warrants, (Month/Day/Year)  A. Deemed Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Acquee.g., puts, calls, warrants, (A) or Disposed of (D) (Instr. 3, 4 and 5)	NEUROCRINE BIOS   NBIX   3. Date of Earliest Transaction (I 10/16/2015   4. If Amendment, Date of Original	NEUROCRINE BIOSCIE   NBIX     3. Date of Earliest Transaction (Month 10/16/2015   4. If Amendment, Date of Original Filest   Table I - Non-Derivative Securities Acquired, Dispersion of Execution Date, if any of Exercise Price of Derivative Security   National Price of Derivative Securities Acquired (Month/Day/Year)   NEUROCRINE BIOSCIE   NBIX   3. Date of Earliest Transaction (Month 10/16/2015   4. If Amendment, Date of Original Filest   NBIX   3. Date of Execution Date, if any (Month/Day/Year)   NBIX   2. Transaction Date   Execution Date, if any (Month/Day/Year)   NBIX   3. Date of Earliest Transaction (Month Execution Date, if any (Month/Day/Year)   NBIX   3. Date of Execution Date, if any (Month/Day/Year)   NBIX   3. Date of Earliest Transaction Date, if any (Month/Day/Year)   NBIX   3. Date of Earliest Transaction (Month/Day/Year)   NBIX   3. Date of Earliest Transaction Date, if any (Month/Day/Year)   NBIX   3. Date of Earliest Transaction Date   NBIX   3. Transaction Date   NBIX   NBIX   3. Transaction Date   NBIX   NBIX   3. Transaction Date   NBIX   3. Transacti	NEUROCRINE BIOSCIENCES INBIX   3. Date of Earliest Transaction (Month/Day/Year) 10/16/2015   4. If Amendment, Date of Original Filed (Month/Day/Year)   5. Namer (Month/Day/Year)   5. Namer (Month/Day/Year)   6. Date Execution Date (P.g., puts, Calls, warrants, options, convertibe Security (Instr. 3)   3. Transaction (Month/Day/Year)   7. Source (Month/Day/Year	NEUROCRINE BIOSCIENCES INC   NBIX	NEUROCRINE BIOSCIENCES INC   NBIX	NEUROCRINE BIOSCIENCES INC   Check	NEUROCRINE BIOSCIENCES INC   (Check all application of the price of Original Filed (Month/Day/Year)   Security (Instr. 3)   2. Transaction (Month/Day/Year)   Security (Instr. 3)   2. Transaction (Month/Day/Year)   2. Transaction (Month/Day/Year)   2. Transaction Date (Month/Day/Year)   3.	NEUROCRINE BIOSCIENCES INC   Check all applicable   Director   Check of policy of the policy of th	NEUROCRINE BIOSCIENCES INC   Check all applicable   Director   10% of Other below   Chief Business Development

## **Explanation of Responses:**

1. Sale of 25,000 shares of common stock issued upon vesting of 50,000 restricted stock units on October 15, 2015 to cover payroll and withholding taxes, with the balance of the shares (25,000) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$46.66 to \$49.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

## Remarks:

/s/ Darin Lippoldt, Attorney-infact 10/19/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.